Understanding peptide stability

Four ways a peptide can lose activity

A peptide in a vial appears stable — a white powder or a clear solution that looks the same after a week as it did when it arrived. But the chemistry underneath is not static. Peptides can degrade through at least four distinct mechanisms: hydrolysis of the peptide backbone, oxidation of susceptible amino-acid residues, aggregation of monomers into inactive multimers, and denaturation at air-liquid interfaces. Each mechanism is accelerated by different environmental factors — temperature for hydrolysis, oxygen and light for oxidation, concentration and agitation for aggregation, mechanical disturbance for interface denaturation. Understanding these mechanisms is what lets you read a storage instruction as a coherent chemistry statement rather than a superstitious ritual. It also lets you diagnose why a particular vial might have failed.

Hydrolysis — the water-driven backbone cleavage

The peptide bond is a covalent bond formed by the elimination of water between an amino acid's carboxyl group and the next amino acid's amine group. The reverse reaction — hydrolysis of the peptide bond by addition of water — is thermodynamically favourable but kinetically slow at physiological temperature and pH. However, 'slow' is not 'zero'. Over weeks and months, hydrolytic cleavage of peptide bonds does occur, particularly at labile sites such as aspartate-glycine junctions. The rate accelerates roughly exponentially with temperature — a peptide that is stable for years at −20 °C might be stable for months at 4 °C and only weeks at 25 °C. This is why refrigerator storage is the default for reconstituted vials and why freezer storage is used for long-term reserve. It is also why the lyophilized format is so much more stable than the liquid: removing water essentially arrests the hydrolysis chemistry.

Oxidation — the residue-specific vulnerability

Certain amino-acid residues are susceptible to oxidation by atmospheric oxygen or trace metal-catalysed reactive oxygen species. Methionine is particularly vulnerable (methionine sulfoxide is a common oxidation product), as are cysteine (which can form disulphide bonds or over-oxidise to sulfonic acids) and tryptophan. A peptide's oxidative stability depends on its amino-acid composition and on how solvent-exposed the vulnerable residues are. Oxidation is accelerated by light, oxygen exposure, elevated temperature, and metal ions (which is why some peptide formulations include chelating agents). The practical mitigations are: store in amber or opaque vials to exclude light, minimise headspace air in reconstituted vials, and keep temperature low. Glutathione is a special case here because it is itself a thiol antioxidant — its stability profile involves the reverse-oxidation chemistry that makes it a peptide of interest in the first place.

Aggregation — the concentration-driven multimer problem

Peptides in solution can associate with each other through hydrophobic interactions, electrostatic interactions, or partial-fold intermediates. At low concentration, the peptide remains predominantly monomeric and biologically active. As concentration increases, the probability of intermolecular contacts increases, and stable multimers can form — dimers, trimers, larger aggregates, and eventually visible precipitates. Aggregates lose the biological activity of the monomer (they no longer fit the receptor correctly) and can also become immunogenic if injected. Aggregation is accelerated by high concentration, repeated freeze-thaw cycles, mechanical agitation, and interface exposure. This is why the standard advice is to store reconstituted vials at recommended concentrations rather than concentrating them further, to avoid unnecessary freeze-thaw cycles, and to swirl rather than shake. It is also why any visible cloudiness, precipitate, or particulate matter in a reconstituted vial is a reason to discard the vial — you are seeing aggregation directly.

Interface denaturation — the foam problem

Peptides have hydrophobic and hydrophilic regions distributed along their sequence. In bulk solution the peptide adopts a folded configuration that minimises exposure of hydrophobic residues to water. At an air-liquid interface, however, that configuration is disrupted — the peptide can unfold to expose hydrophobic residues to the air side of the interface. Once unfolded at the interface, the peptide may not refold correctly when it returns to bulk solution, and unfolded peptides are prone to aggregation with other unfolded peptides. Vigorous shaking of a peptide solution generates foam, and the enormous surface area of that foam produces a large air-liquid interface where denaturation happens quickly. This is why every reconstitution instruction says to swirl the vial gently rather than shake it, and why directing the diluent stream down the vial wall rather than onto the powder matters — both techniques minimise foam and therefore minimise interface denaturation. The chemistry is real; the practice is not superstition.

Common questions